Key Takeaways:
- Poolbeg Pharma shares rose 9% after positive FDA pre-IND meeting for POLB 001
- Cavendish reiterated buy rating and 19p target, citing de-risked development pathway
- Interim data from the TOPICAL trial expected this summer
Back
Poolbeg Pharma jumps 9% after FDA alignment de-risks cancer therapy
Poolbeg Pharma shares rose 9% after the FDA agreed with its development plan for POLB 001, a cancer immunotherapy side-effect treatment.
"The FDA feedback de-risks the overall development programme by ensuring the regulator agrees the data could support approval," Cavendish analysts said in a note, reiterating their buy rating and 19 pence price target.
The pre-IND meeting covered key aspects of Poolbeg's strategy, including agreement on the primary endpoint for a future Phase III trial. The company plans to start the TOPICAL study, testing POLB 001 in about 30 patients with relapsed or refractory multiple myeloma receiving a bispecific antibody, with interim data expected this summer.
The FDA alignment strengthens Poolbeg's hand in partnering discussions by giving potential licensees greater confidence in the route to market, Cavendish said. The broker's 19p target implies 245% upside from the current 5.5p share price, which values the company at £35.1 million.
POLB 001 is being developed as a preventative therapy for cytokine release syndrome, a serious complication of immunotherapies including bispecific antibodies. Poolbeg estimates peak sales potential in the multi-billion-dollar range in the US alone, within a total addressable market exceeding $10 billion. That estimate covers relapsed or refractory multiple myeloma and diffuse large B-cell lymphoma. Recent payer research covering about 75 million lives validated both the unmet need and insurer appetite for an effective preventative approach, according to Cavendish.
Beyond POLB 001, Poolbeg expects to start a proof-of-concept study for an oral GLP-1 obesity treatment in the second half of 2026.
The FDA feedback removes a key regulatory uncertainty for Poolbeg's lead asset, making a partnership or licensing deal more likely. Investors will watch for interim TOPICAL data this summer as the next catalyst.
This article is for informational purposes only and does not constitute investment advice.
[1] Cavendish says FDA alignment de-risks Poolbeg Pharma's lead cancer therapy programme for partners[2] Poolbeg Pharma gets positive FDA feedback for development pathway of lead cancer therapy asset[3] Cavendish says FDA alignment de-risks Poolbeg Pharma's lead cancer therapy programme for partners - Proactive financial news[4] Poolbeg Pharma Says FDA Feedback Broadly Aligned With Development Pathway For POLB 001 - TradingView
